Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 31, 2012, Pages 12722-12727

  Cheng, Christine K ^a   Gustafson, W Clay ^a   Charron, Elizabeth ^a   Houseman, Benjamin T ^a   Zunder, Eli ^a   Goga, Andrei ^a   Gray, Nathanael S ^a   Pollok, Brian ^b   Oakes, Scott A ^a,c   James, C David ^a   Shokat, Kevan M ^a,c   Weiss, William A ^a   Fan, Qi Wen ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b INVITROGEN CORPORATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; MK 7965; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIK 75; PIK 90; PROTEIN KINASE B; ROSCOVITINE; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; EMBRYO; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CDC2 PROTEIN KINASE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 2; FEMALE; GLIOMA; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PURINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864504656     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1202492109     Document Type: Article

References (29)

1. Wong AJ, et al. (1987) Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84:6899-6903.
2. Humphrey PA, et al. (1988) Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48:2231-2238.
3. Cancer Genome Atlas Research Network(2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
4. Fung AS, Wu L, Tannock IF (2009) Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin Cancer Res 15:5389-5395.
5. Fan QW, et al. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9:341-349.
6. Fan QW, et al. (2007) A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67:7960-7965.
7. Knight ZA, et al. (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125:733-747.
8. Hayakawa M, et al. (2007) Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 15:5837-5844. (Pubitemid 47043472)
9. Hayakawa M, et al. (2007) Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 15:403-412. (Pubitemid 44738565)
10. Schmid AC, Byrne RD, Vilar R, Woscholski R (2004) Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett 566:35-38. (Pubitemid 38625928)
11. Mirza AM, Kohn AD, Roth RA, McMahon M (2000) Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB. Cell Growth Differ 11:279-292. (Pubitemid 30457777)
12. Wei MC, et al. (2001) Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 292:727-730. (Pubitemid 32385543)
13. Lindsten T, et al. (2000) The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 6:1389-1399. (Pubitemid 32045931)
14. Hu B, Mitra J, van den Heuvel S, Enders GH (2001) S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol Cell Biol 21:2755-2766. (Pubitemid 32244920)
15. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 9:153-166.
16. Benson C, et al. (2007) A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96:29-37. (Pubitemid 46094635)
17. Hsieh WS, et al. (2009) Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin Cancer Res 15:1435-1442.
18. Hui AB, et al. (2009) Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. Clin Cancer Res 15:3716-3724.
19. Sarkaria JN, et al. (2006) Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 12:2264-2271.
20. Kim EH, Kim SU, Shin DY, Choi KS (2004) Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 23:446-456. (Pubitemid 38174999)
21. Hirai H, et al. (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9:1956-1967.
22. Parry D, et al. (2010) Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 9:2344-2353.
23. Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547-566.
24. Maira SM, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7(7):1851-1863.
25. Fan QW, Weiss WA (2005) RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. Oncogene 24:829-837.
26. Campeau E, et al. (2009) A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS ONE 4:e6529.
27. Fan QW, et al. (2010) Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 3:ra81.
28. Fan QW, et al. (2003) Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res 63:8930-8938.
29. Committee on Care and Use of Laboratory Animals (1985) Guide for the Care and Use of Laboratory Animals (Natl Inst Health, Bethesda), DHHS Publ No (NIH) 85-23.